These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17083342

  • 1. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M, German CLL Study Group (GCLLSG).
    Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
    [Abstract] [Full Text] [Related]

  • 2. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 01; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct 01; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H.
    J Clin Oncol; 2005 Jun 20; 23(18):4079-88. PubMed ID: 15767648
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 14. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC.
    Semin Oncol; 2000 Apr 20; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR, Foa R, Meloni G, Gentile M, Giammartini E, Giannarelli D, De Propris MS, Rapanotti MC, de Fabritiis P, Mandelli F.
    Haematologica; 2002 Sep 20; 87(9):926-33. PubMed ID: 12217804
    [Abstract] [Full Text] [Related]

  • 16. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E, Kafková A, Fricová M, Guman T, Stecová N.
    Neoplasma; 2003 Sep 20; 50(6):433-7. PubMed ID: 14689065
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR, Gentile M, Mancini F, Giannarelli D, Guarini A, De Propriis MS, Cerretti R, Foa R.
    Haematologica; 2002 Jun 20; 87(6):602-8. PubMed ID: 12031916
    [Abstract] [Full Text] [Related]

  • 18. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA, Stadnik EA, Lorie IuIu, Biderman BV, Tsyba NN, Salogub GN, Kolosheĭnova TI, Kolosova LIu, Risinskaia NA, Zaritskiĭ IuA, Kovaleva LG, Sudarikov AB.
    Ter Arkh; 2007 Jun 20; 79(7):66-70. PubMed ID: 17802794
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
    Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM.
    Cancer Chemother Pharmacol; 2003 Sep 20; 52(3):223-8. PubMed ID: 12783199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.